Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus Radiotherapy for PCNSL
NCT00002676Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 1995
- Primary completion
- Oct 2006
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, dexamethasone, carmustine and 2 more in primary central nervous system lymphoma (PCNSL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Response rate up to 10 years. Started Jul 1995; status: completed.
02
Drugs
cyclophosphamidedoxorubicinvincristinedexamethasonecarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00002676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002676.